Silence Therapeutics plc
NASDAQ:SLN · NASDAQ Global Market
+$0.19 today
Vol 0.38M · Avg 0.31M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:SLN · Revenue to Net Income
Key Ratios
Analysis
$921.5K of revenue converted into -$85.2M of net income for the selected period. Gross margin is 64.7% and net margin is -15888.7%, showing how much revenue survives after costs and taxes. EPS is $-4.32, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $559.0K -98.7% | $43.3M +70.5% | $25.4M +43.7% | $17.7M +42.2% | $12.4M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $215.0K -98.2% | $11.8M +14.5% | $10.3M -6.0% | $11.0M +47.2% | $7.5M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $344.0K -98.9% | $31.4M +108.9% | $15.1M +125.5% | $6.7M +34.7% | $5.0M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 61.5% -11.2pp | 72.7% +13.4pp | 59.3% +21.5pp | 37.8% -2.1pp | 39.9% | 9.8% | 28.9% | 38.3% |
| Research & Development | $67.8M -0.2% | $67.9M +54.2% | $44.0M +24.0% | $35.5M +15.4% | $30.8M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $22.3M -16.9% | $26.9M +30.3% | $20.6M -1.4% | $20.9M +4.6% | $20.0M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $90.1M -4.9% | $94.8M +46.6% | $64.7M +14.6% | $56.4M +11.2% | $50.8M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $555.0K -6.4% | $593.0K +19.1% | $498.0K +2.5% | $485.9K +13.8% | $427.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$88.0M -79.7% | -$49.0M +1.6% | -$49.8M -24.6% | -$39.9M +12.1% | -$45.4M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -15750.6% -15637.4pp | -113.2% +82.9pp | -196.2% +30.1pp | -226.2% +139.6pp | -365.9% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$89.8M -41.7% | -$63.3M -27.6% | -$49.6M +0.3% | -$49.8M -8.6% | -$45.8M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -16056.0% -15909.6pp | -146.4% +49.1pp | -195.5% +86.4pp | -281.9% +87.1pp | -369.0% | 16.6% | 24.1% | 22.0% |
| Interest Income | $3.5M -22.2% | $4.5M +209.3% | $1.4M +539.8% | $226.0K +2160.0% | $10.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 -100.0% | $34.0K -27.7% | $47.0K +487.5% | $8.0K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $1.2M -93.9% | $18.9M +2770.7% | -$706.0K -107.6% | $9.3M +22215.1% | -$42.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$88.6M -99.3% | -$44.5M +11.6% | -$50.3M -24.3% | -$40.5M +11.7% | -$45.9M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -15849.9% -15747.1pp | -102.8% +95.5pp | -198.3% +31.0pp | -229.3% +140.1pp | -369.4% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $11.0K -98.7% | $845.0K +112.0% | -$7.0M -1355.8% | $560.9K +108.7% | -$6.4M | $1.3B | -$1.6B | $745.2M |
| Net Income | -$88.6M -95.6% | -$45.3M -4.7% | -$43.3M -5.4% | -$41.0M -4.1% | -$39.4M | $4.9B | $4.8B | $4.7B |
| Net Margin | -15851.9% -15747.1pp | -104.7% +65.8pp | -170.5% +61.9pp | -232.4% +85.0pp | -317.4% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$2 +20.3% | -$2 +31.9% | -$3 +7.9% | -$4 -180.0% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$2 +20.3% | -$2 +31.9% | -$3 +7.9% | -$4 -180.0% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $47.2M +206.4% | $15.4M +24.7% | $12.4M +15.2% | $10.7M -63.8% | $29.7M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $47.2M +206.4% | $15.4M +24.7% | $12.4M +15.2% | $10.7M -63.8% | $29.7M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Capricor Therapeutics, Inc.
NASDAQ:CAPR
$1.30B
Alto Neuroscience, Inc.
NYSE:ANRO
$782.59M
Contineum Therapeutics, Inc. Class A Common Stock
NASDAQ:CTNM
$443.03M
Lexeo Therapeutics, Inc. Common Stock
NASDAQ:LXEO
$389.86M
Kyverna Therapeutics, Inc.
NASDAQ:KYTX
$348.58M
Amarin Corporation plc
NASDAQ:AMRN
$332.17M
Lyell Immunopharma, Inc.
NASDAQ:LYEL
$292.84M
AC Immune S.A.
NASDAQ:ACIU
$241.71M
Aldeyra Therapeutics, Inc.
NASDAQ:ALDX
$117.02M
Mereo BioPharma Group plc
NASDAQ:MREO
$50.52M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does SLN generate?
Silence Therapeutics plc (SLN) reported $559,000.00 of revenue in fiscal 2025.
Is SLN profitable?
Silence Therapeutics plc (SLN) reported -$88,612,000.00 of net income, with a net margin of -15851.9%.
Explore More
Continue the stock analysis
Jump to another research area for this company.